ClinicalTrials.gg
RecruitingNCT07430202Updated Oct 30, 2026

A DNAJB1-PRKACA Fusion Kinase Peptide Vaccine Combined With Glutamine Antagonist DRP-104, Nivolumab, and Ipilimumab in Patients With Advanced Stage Fibrolamellar Carcinoma (FLC)

A Phase 1 interventional study of DNAJB1-PRKACA Peptide Vaccine and DRP-104 in Liver Cancer (Fibrolamellar Hepatocellular Cancer (FLC)), sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. Recruiting at 1 site in United States. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2026-10-30.

Primary conditionFibrolamellar hepatocellular carcinomaRegistry: Liver NeoplasmsReclassifiedWhy we changed it
Registry
Liver Neoplasms — the first condition term the registry derived for this study.
ClinicalTrials.gg
Fibrolamellar hepatocellular carcinoma
Why
  1. The study's title name Fibrolamellar hepatocellular carcinoma, a narrower term within Liver Neoplasms.
Confidence
High: the new condition is named in the study's own title. Of 46 hand-checked studies reclassified this way, 72% were exactly right and 89% in the right disease family; the registry's first term was right for 4% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · Phase 1, Interventional, and Treatment

How we know · 9 judgments

Updated Oct 5, 2026Now RecruitingSite recruiting status changed+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
27
Allocation
Not applicable
Ages
12 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 13 studies in Fibrolamellar hepatocellular carcinoma with a site in United States — 4 open to participants now, 8 under way, 1 of them phase 3. Fibrolamellar hepatocellular carcinoma · United States.

Planned enrollment
9th of 12
27 · median 60
Started
2026
the only one that year
Phase 1
4 of 13
2 open now
Registered
13th of 13
by date
Lead sponsor
4 of 13
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Among the 13 studies in Fibrolamellar hepatocellular carcinoma with a site in United States, this one is the 9th largest by planned enrollment of the 12 interventional ones that give a count, is the only one that started in 2026, is one of 4 in phase 1, and was the 13th registered.

Fibrolamellar hepatocellular carcinoma

20 studies on the registry are indexed under Fibrolamellar hepatocellular carcinoma; 8 are open to participants now.

Browse Fibrolamellar hepatocellular carcinoma studies →

Open to participants now

4 of the 13 studies in Fibrolamellar hepatocellular carcinoma with a site in United States are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 7 Fibrolamellar hepatocellular carcinoma studies recruiting now, 5 set no upper age limit and 2 stop at 75 or younger; 5 take children under 18; none take healthy volunteers.

This study: 12 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies in Fibrolamellar hepatocellular carcinoma with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to determine whether the combination of a neoantigen vaccine targeting the DNAJB1-PRKACA fusion kinase in combination with DRP-104, Nivolumab and Ipilimumab is safe and yields a clinically compelling antitumor activity measured as based on objective response rate (ORR, assessed by RECIST 1.1). Secondary objectives include progression-free survival (PFS) and overall survival (OS).

03

Conditions studied

  • Liver Cancer (Fibrolamellar Hepatocellular Cancer (FLC))

Browse trials for

Keywords

  • Fibrolamellar Carcinoma (FLC)
  • Liver Cancer
  • DNAJB1-PRKACA Fusion Kinase Peptide Vaccine
  • DRP-104 (glutamine antagonist peptide)
  • Nivolumab
  • Ipilimumab
  • Immunotherapy
  • Anti PD-L1 (Anti-Programmed Death Ligand 1)
  • PD-L1 (Programmed Death Ligand 1)
  • Carcinoma
  • Glutamine antagonist
04

In context

Fibrolamellar hepatocellular carcinoma Reclassified

20 studies on the registry are indexed under Fibrolamellar hepatocellular carcinoma; 8 are open to participants now.

This study's planned enrollment of 27 is close to the median of 28 across 17 interventional studies indexed under Fibrolamellar hepatocellular carcinoma.

Browse Fibrolamellar hepatocellular carcinoma studies →

Lead sponsor

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins is the lead sponsor of 582 studies on the registry; 71 are open to participants now.

Of its 114 completed or terminated interventional studies of FDA-regulated products, 68 (60%) have results posted.

Compared within Fibrolamellar hepatocellular carcinoma, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Liver Neoplasms. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
12 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Must have confirmed FLC that is or unresectable.
  • Presence of DNAJB1-PRKACA fusion transcript, assessed by RNA-sequencing, DNA-sequencing, or in situ hybridization in the .
  • Must have demonstrated radiographic progression on prior or current immunotherapy.
  • Age ≥ 12 years.
  • Patients \< 18 years old must have a body weight ≥ 40 kg.
  • (Eastern Cooperative Oncology Group) performance status of ≤2
  • Patients must have adequate organ and marrow function defined by study-specified laboratory tests.
  • Patients must have adequate kidney and liver function defined by study-specified laboratory tests.
  • Must have per 1.1
  • Willingness to provide tissue and blood samples for mandatory translational research.
  • Women of (WOCBP) must have a negative urine or serum pregnancy test.
  • For both Women and Men, must use acceptable form of while on study.
  • Ability to understand and willingness to sign a written document.

Exclusion criteria

Exclusion Criteria:

  • Patients with a history of prior treatment with , such as anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, anti-OX-40, anti-0, anti-CTLA-4, or anti-LAG-3 antibodies.
  • Must have had chemotherapy or other systemic therapy or radiotherapy, as follows:

    • Patients who have had chemotherapy, biological cancer therapy, or radiation 14 days prior to the first dose of study drug.
    • Patients who have had surgery within 28 days of dosing of agent, excluding minor procedures.
    • Patients who have received other approved or investigational agents or device within 28 days of the first dose of study drug.
  • Patients who have not recovered from acute adverse events to grade ≤1 or baseline due to agents administered, with exception of grade 2 fatigue, rash, and endocrinopathy successfully managed hormone replacement therapy, or alopecia or stable neuropathy, unless approved by the IND Sponsor.
  • Patients who have received any non-oncology therapy used for prevention of infectious diseases within 28 days of study treatment.
  • Known sensitivity to or history of allergic reactions attributed to compounds of similar chemical or biologic composition of polyinosinic-polycytidylic acid (Poly-ICLC) and/or DRP-104 and/or nivolumab and/or ipilimumab.
  • History of severe reaction to any monoclonal antibody.
  • Has an active disease.
  • Prior stem cell transplantation or organ transplantation.
  • Has a diagnosis of immunodeficiency.
  • Systemic at doses.
  • Subjects with interstitial lung disease that is symptomatic or may interfere with the detection or management of suspected drug-related pulmonary toxicity.
  • Has a pulse oximetry of \<92% on room air or is on supplemental home oxygen.
  • Active or untreated or .
  • Uncontrolled intercurrent active medical and/or psychiatric illness/social psychosocial problems that that would limit compliance with study requirements.
  • Uncontrolled intercurrent illness including, but not limited to, uncontrolled infection, symptomatic congestive heart failure, unstable angina, cardiac arrhythmia, cancer, or psychiatric illness/social situations that would limit compliance with study requirements.
  • Pregnant or breastfeeding.
  • Has a known history of (HIV)/AIDS.
  • Has active . Patients with chronic or acute HBV infection.
  • Have had evidence of active or acute diverticulitis, intra-abdominal abscess, or GI obstruction which are known risk factors for bowel perforation should be evaluated for the potential need for additional treatment before coming on study.
  • Unwilling or unable to follow the study schedule for any reason.
  • Patient is at the time of signing a regular user (including "recreational use") of any illicit drugs or had a recent history (within the last year) of substance abuse (including alcohol).
  • Evidence of clinical ascites.
  • Patients with prolongation > 470 ms according to Fridericia formula.
  • Patients receiving potent inducers of CYP 3A4/5 (including but not limited to apalutamide, carbamazepine, enzalutamide, mitotane, phenytoin, rifampin and St. John's Wort) who cannot safely discontinue drug at least 14 days prior to Cycle 1 Day 1.
  • Have had an allergen hyposensitization therapy within 2 weeks prior to initiation of study treatment.
Terms in these criteria, in plain language(23)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

06

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
27 participants (estimated)

Study arms

  • Experimental
    Arm A - DNAJB1-PRKACA Peptide Vaccine with poly-ICLC adjuvant, DRP-104, Nivolumab and Ipilimumab

    Drug: DNAJB1-PRKACA Peptide Vaccine · Drug: DRP-104 · Drug: Nivolumab · Drug: Ipilimumab

Interventions

  • DrugDNAJB1-PRKACA Peptide Vaccine

    1. Patients will receive treatment on Day 1, 8 and 15 of cycle 1 and on Day 1 of cycle 2, 3, and 4 (Prime Phase). Boost vaccinations will be administered every 3 cycles beginning from C5D1. 2. Drug: 0.3 mg DNAJB1-PRKACA peptide vaccine + 0.5 mg Poly-ICLC

    Also known as: Hiltonol® (Poly-ICLC)

  • DrugSirpiglenastatStudies of SirpiglenastatSirpiglenastat pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    1. Patients will receive treatment on Day 1, 4, 8, 11, 15, and 18 of cycle 1-4 (Prime Phase) then on Days 1, 4, 8, 11, 15, 18, 22 and 25 of each cycle starting on Day 1 of Cycle 5 (Boost/maintenance Phase). DRP-104 will be administered as a subcutaneous injection twice a week (BIW) on a continuous schedule for up to two years. 2. Drug: 145 mg

  • 1. Patients will receive treatment on Day 1 of each Cycle. Nivolumab 3mg/kg will be administered every 3 weeks as a 30 minute IV infusion (-10/+15min) on Day 1 of Cycle 1-4 (Prime Phase). Nivolumab infusions will be administered as a flat dose of 480mg every 4 weeks starting on Day 1 of Cycle 5 (Boost/maintenance). 2. Drug: 3mg/kg and 480mg IV

    Also known as: OPDIVO

  • 1. Patients will receive treatment on Day 1 of Cycle 1-4 (Prime Phase). Ipilimumab (1 mg/kg) will be administered. Ipilimumab (1 mg/kg) will be administered as a 30 minute IV infusion (-10/+15min). 2. Drug: 1mg/kg IV

    Also known as: YERVOY®

07

What researchers measure

Primary outcomes

  1. Number of participants experiencing grade 3 or above drug-related toxicities

    When calculating the incidence of AEs, each AE (as defined by NCI CTCAE v6.0) will be counted only once for a given subject.

    Time frame: 4 years

  2. Objective response rate (ORR) using immune Response Evaluation Criteria for Solid Tumors (RECIST 1.1)

    ORR is defined as the percentage of patients achieving a complete response (CR) or partial response (PR) to DRP-104 in combination with DRP-104, Nivolumab and Ipilimumab, based on the immune Response Evaluation Criteria in Solid Tumors (RECIST 1.1) at any time during the study. CR = disappearance of all target lesions, PR is =\>30percent decrease in sum of diameters of target lesions, progressive disease (PD) is \>20percent increase in sum of diameters of target lesions, stable disease (SD) is \<30percent decrease or \<20percent increase in sum of diameters of target lesions.

    Time frame: 4 years

Secondary outcomes

  1. Progression-free Survival (PFS) number of months according to RECIST (1.1) criteria.

    PFS is defined as the number of months from the date of first treatment to disease progression (progressive disease \[PD\] or relapse from complete response \[CR\] as assessed using RECIST 1.1 criteria) or death due to any cause. Per RECIST 1.1 criteria, CR = disappearance of all target lesions, Partial Response (PR) is =\>30% decrease in sum of diameters of target lesions, Progressive Disease (PD) is \>20% increase in sum of diameters of target lesions, Stable Disease (SD) is \<30% decrease or \<20% increase in sum of diameters of target lesions.

    Time frame: 4 years

  2. Overall survival (OS) of patients treated with study drug combination

    OS is defined as the number of months from the first dose of study treatment to death from any cause. (OS will be censored on the date the subject was last known to be alive for subjects without documentation of death at the time of analysis). Estimation based on the Kaplan-Meier curve.

    Time frame: 4 years

08

Study locations

1 of 1 sites recruiting
09

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

10

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started Oct 2026 (actual). Primary completion is estimated for Oct 2030, 48 months after the start.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 5, 2026: start Sep 2026 → Oct 2026, primary completion Sep 2030 → Oct 2030 and completion Sep 2030 → Oct 2030.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Feb 18, 2026
First posted
Feb 24, 2026
StartActual
Oct 28, 2026was Sep 2026
Primary completionEst.
Oct 2030was Sep 2030
CompletionEst.
Oct 2030was Sep 2030
Last update
Oct 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Oct 5, 2026
Sites
Johns Hopkins SKCCC is now Recruiting
Oct 5, 2026
Start date
Sep 2026→Oct 2026
Oct 5, 2026
Primary completion
Sep 2030→Oct 2030
Oct 5, 2026
Study completion
Sep 2030→Oct 2030
Oct 5, 2026
Show all 2 updates
  1. Oct 30, 2026
    Minor edits only
    + 1 other change: date precision
  2. Oct 5, 2026
    Not yet recruiting→Recruiting
    Johns Hopkins SKCCC is now Recruiting
    Start date Sep 2026→Oct 2026
    Primary completion Sep 2030→Oct 2030
    Study completion Sep 2030→Oct 2030
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT07430202
Collaborators
Dracen Pharmaceuticals, Inc., Cancer Research Institute, New York City, Fibrolamellar Cancer Foundation
Responsible party
Sponsor
First posted
Feb 24, 2026
Start date
Oct 28, 2026
Primary completion
Oct 2030 (estimated)
Completion
Oct 2030 (estimated)
Last update
Oct 30, 2026

Study contacts

Colleen Apostol, RN
Contact
GIClinicalTrials@jhmi.edu
410-614-3644
Marina Baretti, MD
principal investigator · SKCCC • Johns Hopkins Medical Institution

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sirpiglenastat

Start the discussion